VivoSim Labs (VIVS) Change in Account Payables (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Change in Account Payables of $350000.0 for Q1 2026, down 50.98% year-over-year from $714000.0 in Q1 2025, and up 284.62% quarter-over-quarter from $91000.0 in Q4 2025.
VivoSim Labs (VIVS) Change in Account Payables (2011 - 2026) Analysis & Trends
VivoSim Labs' Change in Account Payables history runs 16 years deep, the most recent figure standing at $350000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 50.98% year-over-year to $350000.0; the TTM figure through Mar 2026 stood at -$623000.0 (down 161.26% YoY), while the FY2026 annual figure was -$623000.0, down 161.26% from the prior year.
- Change in Account Payables for Q1 2026 stood at $350000.0, up from $91000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $714000.0 in Q1 2025, with the low at -$971000.0 in Q2 2025.
- The 5-year median for Change in Account Payables is $36000.0 (2023), against an average of $20705.9.
- Peak annual rise in Change in Account Payables reached 1319.44% in 2024, while the deepest fall reached 1220.75% in 2024.
- VivoSim Labs' Change in Account Payables stood at -$199000.0 in 2022, then jumped by 118.09% to $36000.0 in 2023, then jumped by 1319.44% to $511000.0 in 2024, then plunged by 82.19% to $91000.0 in 2025, then surged by 284.62% to $350000.0 in 2026.
- Business Quant data shows VIVS's Change in Account Payables at $350000.0 in Q1 2026, $91000.0 in Q4 2025, and -$93000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -400,000.00 |
| Jun 30, 2026 | -400,000.00 |
| Mar 31, 2026 | 350,000.00 |
| Mar 31, 2026 | 350,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Dec 31, 2025 | 91,000.00 |
| Sep 30, 2025 | -93,000.00 |
| Sep 30, 2025 | -93,000.00 |
| Jun 30, 2025 | -971,000.00 |
| Jun 30, 2025 | -971,000.00 |
| Mar 31, 2025 | 714,000.00 |
| Mar 31, 2025 | 714,000.00 |
| Dec 31, 2024 | 511,000.00 |
| Dec 31, 2024 | 511,000.00 |
| Sep 30, 2024 | -700,000.00 |
| Sep 30, 2024 | -700,000.00 |
| Jun 30, 2024 | 492,000.00 |
| Jun 30, 2024 | 492,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Mar 31, 2024 | 156,000.00 |